Malta - English - Medicines Authority

mcneil products limited foundation park, roxborough way, maidenhead, berkshire sl6 3ug, united kingdom - diphenhydramine hydrochloride, paracetamol, pseudoephedrine hydrochloride - oral solution - diphenhydramine hydrochloride 25 µg/dose paracetamol 1000 µg/dose pseudoephedrine hydrochloride 45 µg/dose - cough and cold preparations

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - fexofenadine hydrochloride 60 mg - allegra-d 12 hour extended-release tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. symptoms treated effectively include sneezing, rhinorrhea, itchy nose/palate/ and/or throat, itchy/watery/red eyes, and nasal congestion. allegra-d 12 hour should be administered when both the antihistaminic properties of fexofenadine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired (see clinical pharmacology). allegra-d 12 hour is contraindicated in patients with known hypersensitivity to any of its ingredients. due to its pseudoephedrine component, allegra-d 12 hour is contraindicated in patients with narrow-angle glaucoma or urinary retention, and in patients receiving monoamine oxidase (mao) inhibitor therapy or within fourteen (14) days of stopping such treatment (see drug interactions section). it is also contraindicated in patients with severe hypertension, or severe coronary arter

United States - English - NLM (National Library of Medicine)

stat rx usa llc - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - fexofenadine hydrochloride 180 mg - allegra-d 24 hour extended-release tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. symptoms treated effectively include sneezing, rhinorrhea, itchy nose/palate/ and/or throat, itchy/watery/red eyes, and nasal congestion. allegra-d 24 hour should be administered when both the antihistaminic properties of fexofenadine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired (see clinical pharmacology). allegra-d 24 hour is contraindicated in patients with known hypersensitivity to any of its ingredients. due to its pseudoephedrine component, allegra-d 24 hour is contraindicated in patients with narrow-angle glaucoma or urinary retention, and in patients receiving monoamine oxidase (mao) inhibitor therapy or within fourteen (14) days of stopping such treatment (see drug interactions section). it is also contraindicated in patients with severe hypertension, or severe co

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - fexofenadine hydrochloride 180 mg - allegra-d 24 hour extended-release tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. symptoms treated effectively include sneezing, rhinorrhea, itchy nose/palate/ and/or throat, itchy/watery/red eyes, and nasal congestion. allegra-d 24 hour should be administered when both the antihistaminic properties of fexofenadine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired (see clinical pharmacology). allegra-d 24 hour is contraindicated in patients with known hypersensitivity to any of its ingredients. due to its pseudoephedrine component, allegra-d 24 hour is contraindicated in patients with narrow-angle glaucoma or urinary retention, and in patients receiving monoamine oxidase (mao) inhibitor therapy or within fourteen (14) days of stopping such treatment (see drug interactions section). it is also contraindicated in patients with severe hypertension, or severe coronary arter

United States - English - NLM (National Library of Medicine)

acella pharmaceuticals, llc - brompheniramine maleate (unii: ixa7c9zn03) (brompheniramine - unii:h57g17p2fn), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f), dextromethorphan hydrobromide (unii: 9d2rti9kyh) (dextromethorphan - unii:7355x3rots) - brompheniramine maleate 2 mg in 5 ml - brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup is indicated for relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. hypersensitivity to any of the ingredients. do not use in the newborn, in premature infants, in nursing mothers, or in patients with severe hypertension or severe coronary artery disease. do not use dextromethorphan in patients receiving monoamine oxidase inhibitors (maois) (see drug interactions ). antihistamines should not be used to treat lower respiratory tract conditions including asthma.

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - brompheniramine maleate (unii: ixa7c9zn03) (brompheniramine - unii:h57g17p2fn), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f), dextromethorphan hydrobromide (unii: 9d2rti9kyh) (dextromethorphan - unii:7355x3rots) - brompheniramine maleate 2 mg in 5 ml - brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup is indicated for relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. hypersensitivity to any of the ingredients. do not use in the newborn, in premature infants, in nursing mothers, or in patients with severe hypertension or severe coronary artery disease. do not use dextromethorphan in patients receiving monoamine oxidase inhibitors (maois) (see drug interactions ). antihistamines should not be used to treat lower respiratory tract conditions including asthma.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - fexofenadine hydrochloride,pseudoephedrine hydrochloride -

United States - English - NLM (National Library of Medicine)

proficient rx lp - brompheniramine maleate (unii: ixa7c9zn03) (brompheniramine - unii:h57g17p2fn), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f), dextromethorphan hydrobromide (unii: 9d2rti9kyh) (dextromethorphan - unii:7355x3rots) - brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup is indicated for relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. hypersensitivity to any of the ingredients. do not use in the newborn, in premature infants, in nursing mothers, or in patients with severe hypertension or severe coronary artery disease. do not use dextromethorphan in patients receiving monoamine oxidase inhibitors (maois) (see drug interactions ). antihistamines should not be used to treat lower respiratory tract conditions including asthma.

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - brompheniramine maleate (unii: ixa7c9zn03) (brompheniramine - unii:h57g17p2fn), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f), dextromethorphan hydrobromide (unii: 9d2rti9kyh) (dextromethorphan - unii:7355x3rots) - brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup is indicated for relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. hypersensitivity to any of the ingredients. do not use in the newborn, in premature infants, in nursing mothers, or in patients with severe hypertension or severe coronary artery disease. do not use dextromethorphan in patients receiving monoamine oxidase inhibitors (maois) (see drug interactions ). antihistamines should not be used to treat lower respiratory tract conditions including asthma.

United States - English - NLM (National Library of Medicine)

edwards pharmaceuticals, inc. - pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f), triprolidine hydrochloride (unii: yan7r5l890) (triprolidine - unii:2l8t9s52qm) - pseudoephedrine hydrochloride 60 mg - temporarily relieves these symptoms due to the common cold, hay fever (allergic rhinitis) or other upper respiratory allergies: - runny nose - sneezing - itching of the nose or throat - itchy, watery eyes - nasal congestion - reduces swelling of nasal passages